According to the Zhitong Finance App, Qiming Medical-B (02500) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 491 million yuan (RMB, same below) during the period, an increase of 20.89% over the previous year; gross profit of 389 million yuan, an increase of 23.95% over the previous year.

The announcement stated that during the reporting period, all of the Group's revenue was generated from sales of medical devices. Since Venusa-Valve commercialized in August 2017, sales of Venusa-Valve have formed a major part of the Group's revenue and are expected to continue to be an important part of the Group's sales in the future. Venusp-Valve was certified by the European Union CEMDR on April 8, 2022, and approved for listing by the NMPA on July 11, 2022.

The increase in revenue was mainly due to continued commercialization of Venusa series products during the reporting period and VenusP-Valve's increased penetration into overseas markets. Sales revenue of VenUSA series products accounted for 83.4% of the Group's total revenue for the year ended December 31, 2023, and 88.1% of total revenue for the year ended December 31, 2022.